Biophytis (ALBPS) Stock Overview
A clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients with age-related diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
ALBPS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Biophytis S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.058 |
| 52 Week High | €0.40 |
| 52 Week Low | €0.055 |
| Beta | 0.29 |
| 1 Month Change | -4.91% |
| 3 Month Change | -43.04% |
| 1 Year Change | -80.07% |
| 3 Year Change | -99.65% |
| 5 Year Change | -99.90% |
| Change since IPO | -99.90% |
Recent News & Updates
Shareholder Returns
| ALBPS | FR Biotechs | FR Market | |
|---|---|---|---|
| 7D | -7.9% | 1.0% | 1.2% |
| 1Y | -80.1% | 303.2% | 1.2% |
Return vs Industry: ALBPS underperformed the French Biotechs industry which returned 303.3% over the past year.
Return vs Market: ALBPS underperformed the French Market which returned 1.2% over the past year.
Price Volatility
| ALBPS volatility | |
|---|---|
| ALBPS Average Weekly Movement | 12.5% |
| Biotechs Industry Average Movement | 9.1% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in FR Market | 11.3% |
| 10% least volatile stocks in FR Market | 2.4% |
Stable Share Price: ALBPS's share price has been volatile over the past 3 months compared to the French market.
Volatility Over Time: ALBPS's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of French stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 19 | Stanislas Veillet | www.biophytis.com |
Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients with age-related diseases. The company’s lead drug candidate is the BIO101 to treat obesity, respiratory infections due to Covid-19, sarcopenia, and Duchenne Muscular Dystrophy (DMD). It has a collaboration agreement with AFM-Telethon for the development of its BIO101 for the treatment of DMD.
Biophytis S.A. Fundamentals Summary
| ALBPS fundamental statistics | |
|---|---|
| Market cap | €1.36m |
| Earnings (TTM) | -€8.03m |
| Revenue (TTM) | n/a |
Is ALBPS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALBPS income statement (TTM) | |
|---|---|
| Revenue | €0 |
| Cost of Revenue | €0 |
| Gross Profit | €0 |
| Other Expenses | €8.03m |
| Earnings | -€8.03m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.34 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -98.7% |
How did ALBPS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/07 08:34 |
| End of Day Share Price | 2026/02/06 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Biophytis S.A. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Raghuram Selvaraju | H.C. Wainwright & Co. |
| Joseph Pantginis | H.C. Wainwright & Co. |